What is InpharmD?
InpharmD operates at the intersection of pharmacy informatics and clinical decision support. The platform provides a sophisticated, evidence-based repository that synthesizes data from diverse medical studies to offer concise, actionable recommendations. By addressing the critical need for timely and accurate drug information—including side effects, comparative efficacy, and therapeutic applications—InpharmD serves as an essential resource for healthcare professionals navigating high-stakes clinical environments.
The company's market position is defined by its ability to bridge the gap between raw academic research and bedside application. Through its rapid response mechanism, InpharmD empowers pharmacists and clinicians to make informed decisions, thereby improving patient outcomes and optimizing medication management protocols across various healthcare settings.
How much funding has InpharmD raised?
InpharmD has raised a total of $6M across 1 funding round:
Other Financing Round
$6M
Other Financing Round (2023): $6.1M with participation from Atlanta Ventures, 645 Ventures, Qlarant, and Y Combinator
Key Investors in InpharmD
Atlanta Ventures
Atlanta Ventures empowers entrepreneurs in the Southeastern United States by providing community, content, and capital to help them launch and grow their companies.
645 Ventures
645 Ventures is a venture capital firm that invests in seed and Series A SaaS companies, focusing on partnering with innovative founders who aim to transform the future.
Qlarant
Qlarant is a not-for-profit company focused on fighting fraud, waste, and abuse while improving program quality and optimizing performance through data science.
What's next for InpharmD?
With the support of its latest funding round, InpharmD is poised to expand its enterprise footprint and refine its data-driven intelligence capabilities. The strategic roadmap likely includes scaling its infrastructure to accommodate higher query volumes and integrating more advanced analytical tools to provide even more focused, evidence-backed conclusions for its users.
As the healthcare industry continues to prioritize data-driven clinical workflows, InpharmD is well-positioned to capture additional market share. The company's focus on evidence-based medicine, combined with its recent capital infusion, suggests a future trajectory centered on product innovation, broader institutional adoption, and the continued refinement of its clinical informatics ecosystem.
